04.05.23
Amyris, Inc. has completed the previously announced strategic transaction with Givaudan SA for the worldwide exclusive licensing of certain cosmetic ingredients, including Neossance Squalane, Neossance Hemisqualane and CleanScreen.
"We are very pleased with the expansion of our long-term partnership with Givaudan," said John Melo, president and CEO. "This transaction marks the continuation of the successful execution of our strategy to develop, scale and make the world's best-performing molecules from clean, sustainable chemistry and to partner with the world's leading companies. We own the technology, and we formulate and deliver the best-performing consumer products through our portfolio of best-in-category consumer brands, which drives market demand and adoption of our ingredients. Our ingredients partners use their market reach to ensure a steady, reliable supply to leading beauty and personal care companies."
The terms of the deal include a combination of a $200 million upfront cash consideration and up to a $150 million performance based earnout, along with a long-term manufacturing agreement that values the total transaction at an estimated $500 million.
"We are very pleased with the expansion of our long-term partnership with Givaudan," said John Melo, president and CEO. "This transaction marks the continuation of the successful execution of our strategy to develop, scale and make the world's best-performing molecules from clean, sustainable chemistry and to partner with the world's leading companies. We own the technology, and we formulate and deliver the best-performing consumer products through our portfolio of best-in-category consumer brands, which drives market demand and adoption of our ingredients. Our ingredients partners use their market reach to ensure a steady, reliable supply to leading beauty and personal care companies."
The terms of the deal include a combination of a $200 million upfront cash consideration and up to a $150 million performance based earnout, along with a long-term manufacturing agreement that values the total transaction at an estimated $500 million.